Skip to content

Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04346862
Enrollment
636
Registered
2020-04-15
Start date
2016-01-26
Completion date
2020-06-30
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Brief summary

The purpose of this study is to evaluate the efficacy of Acetyl-L-carnitine in patient with Mild Cognitive Impairment associated with chronic cerebrovascular disease.

Interventions

DRUGAcetyl-L-carnitine hydrochloride 500mg

The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks

DRUGPlacebo

The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks

Sponsors

Hanmi Pharmaceutical Company Limited
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age between 55 and 85 years old * Patients with chronic cerebrovascular disease, who have modified Fazekas scale grade 2 \ 3 * Patients wtih a diagnosis of MCI * MOCA-K of 23 or less * Patients who provided a signed written informed consent form

Exclusion criteria

* Patiens who are uneducated or illiterate * Patiens previously treated with dementia * Patients who received a nootropic agent or thyroid hormone within 4 weeks of visit 1 * Patients with cognitive impairment due to diseases other than cerebrovascular disease * Patients with severe depression, schizophrenia, alcoholism, and drug dependence

Design outcomes

Primary

MeasureTime frameDescription
Interference score using K-CWST(Korean-Color Word Stroop Test)24 weekinterference score is defined as 'the time required to test stage 2(Color-Word)' minus ''the time required to test stage 1(Word)
Montreal Cognitive Assessment Korean(MOCA-K)24 weekMOCA-K included cognitive domains; attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. MOCA-K scored from 0 to 30. The higher the score, the better.

Secondary

MeasureTime frameDescription
Korean Trail Making Test Elderly(K-TMT-e)24 weekThe K-TMT-e was composed of 2 parts: part A calls for the test-taker to connect randomly distributed numbers (1-25) on a test paper in ascending order (1-\>2-\>3...), whereas part B requires the test-taker to alternate numbers and letters (1-\>A-\>2-\>B...).
EQ-5D24 weekEQ-5D included 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Clinical Global Impression -Improvement (CGI-I)24 weekCGI-I scored from 1 (very much improved) to 7 (very much worse).

Countries

South Korea

Contacts

Primary ContactJin-A Jung, Ph.D
jajung@hanmi.co.kr82-2-410-9038

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026